SLRN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 113612 min ago

@ $7.58

Išleistas: 14 vas. 2024 @ 17:18

Grąža: -43.93%

Ankstesnis signalas: vas. 13 - 19:30

Ankstesnis signalas: Pardavimas

Grąža: -1.69 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines...

Stats
Šios dienos apimtis	919 490
Vidutinė apimtis	1.25M
Rinkos kapitalizacija	413.69M
EPS	$0 ( 2024-04-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.00800 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Lin Shao-lee	Buy	964 829	Employee Stock Option (right to buy)
2024-01-09	Lin Shao-lee	Buy	413 498	Employee Stock Option (right to buy)
2024-01-09	Labrucherie Gil M	Buy	855 513	Employee Stock Option (right to buy)
2024-01-02	Lin Shao-lee	Sell	10 691	Common Stock
2023-12-18	Tetrault Lynn A.	Buy	89 955	Director Stock Option (right to buy)

INSIDER POWER
-1.36
Last 57 transactions
Buy: 28 627 675 \| Sell: 30 925 812

Tūris Koreliacija

Ilgas: -0.05 (neutral)

Trumpas: 0.32 (neutral)

Signal:(50.901) Neutral

Acelyrin, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Acelyrin, Inc. Koreliacija - Valiuta/Žaliavos

0.39
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.56
( weak negative )

-0.18
( neutral )

Acelyrin, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-12.25

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-12.25

Financial Reports:

No articles found.

Acelyrin, Inc.

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.